Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer
HANGZHOU and SHAOXING, China, Nov. 11, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) , a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Lindi Tan joins Ascletis as Chie...
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD
HANGZHOU, China and SHAOXING, China, Nov. 6, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), a commercial-stage biotechnology company developing innovative drugs to address unmet needs in anti-viral, cancer and fatty liver disease therapeutic areas, announces today that a phase II / III clin...
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA
HANGZHOU and SHAOXING, China, Oct. 18, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announces today the New Drug Application (NDA) of Ravidasvir is on the List of Proposed Priority Review, according to the public notification by the China Food and Drug Administration (CFDA) onOct 17th, 201...
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients
HANGZHOU, China and SHAOXING, China, Oct. 15, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today Ganovo® (Danoprevir) is the only direct-acting anti-viral agent (DAA) eligible for Shaoxing government funding subsidy, according toShaoxing's Action Plan to Accelerate Prevention and...
Ganovo Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program
HANGZHOU and SHAOXING, China, Sept. 26, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today that Ganovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program ("Pilot Program") for outpatients with hepatitis C. The...
Ascletis Appoints Mr. Joshua Zhongbao Ling as VP Finance
HANGZHOU, China and SHAOXING, China, Aug. 30, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today that Mr. Joshua Zhongbao Ling joined Ascletis as Vice President of Finance. Mr. Ling will be responsible for the corporate finance management. "We are excited to have Joshua on board...
